MedTrace Logo

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

NCT04120987 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-07-27

No results posted yet for this study

Summary

To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and postoperative cataract patients.

Conditions

  • Dry Eye

Interventions

DRUG

Lifitegrast 5% Ophthalmic Solution

BID OU

Sponsors & Collaborators

  • Bucci Laser Vision Institute

    lead OTHER

Principal Investigators

  • Frank A Bucci, Jr., MD · Bucci Laser Vision

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2022-06-25
Completion
2022-06-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04120987 on ClinicalTrials.gov